Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.
about
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6BThe Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitisPneumococcal capsular polysaccharide structure predicts serotype prevalenceChanges in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulenceEffects of Streptococcus pneumoniae strain background on complement resistanceBright fluorescent Streptococcus pneumoniae for live-cell imaging of host-pathogen interactions.Contribution of ClpE to virulence of Streptococcus pneumoniae.Role of complement in host defense against pneumococcal otitis mediaStreptococcus pneumoniae phosphotyrosine phosphatase CpsB and alterations in capsule production resulting from changes in oxygen availability.Interaction of pneumococcal histidine triad proteins with human complement.Initiation and synthesis of the Streptococcus pneumoniae type 3 capsule on a phosphatidylglycerol membrane anchor.Nasopharyngeal colonization and invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae.CpsE from type 2 Streptococcus pneumoniae catalyzes the reversible addition of glucose-1-phosphate to a polyprenyl phosphate acceptor, initiating type 2 capsule repeat unit formation.A point mutation in cpsE renders Streptococcus pneumoniae nonencapsulated and enhances its growth, adherence and competence.Contribution of different pneumococcal virulence factors to experimental meningitis in mice.No coexistence for free: neutral null models for multistrain pathogens.The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanismsThe C-type lectin receptor Mincle binds to Streptococcus pneumoniae but plays a limited role in the anti-pneumococcal innate immune response.Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner.Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent Streptococcus pneumoniae capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wallPneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice.Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model.Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy.The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.Pneumococcal virulence gene expression and host cytokine profiles during pathogenesis of invasive disease.Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae.Isolation of Streptococcus pneumoniae biofilm mutants and their characterization during nasopharyngeal colonizationAntibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages.Capsular Polysaccharide Expression in Commensal Streptococcus Species: Genetic and Antigenic Similarities to Streptococcus pneumoniae.Enterococcus faecalis capsular polysaccharide serotypes C and D and their contributions to host innate immune evasionA modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).ComE, an Essential Response Regulator, Negatively Regulates the Expression of the Capsular Polysaccharide Locus and Attenuates the Bacterial Virulence in Streptococcus pneumoniae.Recognition of Streptococcus pneumoniae by the innate immune system.Bacterial interference with canonical NFκB signalling.Inflammasomes in Pneumococcal Infection: Innate Immune Sensing and Bacterial Evasion Strategies.Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.Role of neural barriers in the pathogenesis and outcome of Streptococcus pneumoniae meningitisDendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
P2860
Q24644461-A8E05E0D-84B4-4D90-8663-667F558E639FQ28386753-336FBB43-4C49-4056-BBF2-8A8708FAFC0BQ28475595-2DD44567-5BE1-4FAA-83E9-9BFF77DDEC3CQ28743699-7C09E276-7ABF-4848-8554-B34DB5D61939Q28743913-FEEE62FA-1F8B-4190-B688-EEE9B4C6A2DBQ30620226-808053BC-01AF-487A-A95B-2046A40ACF7EQ30911855-5634BDBE-3FA1-46E2-9629-1E9760426D54Q33399371-0DE8336E-D60D-4B5B-911A-9F7941A065B7Q33570187-DE36698F-7F77-4C90-831E-13837ADE59C9Q33826119-DD74E2F6-0983-4BFB-9EA7-C82A5A120746Q33855730-3A6BE220-8192-4667-8F0B-2698D76BDF24Q34008872-E1AD5B81-E531-432B-A397-872CC8FBF6E5Q34110012-E74C605B-0E26-4050-B921-05523A56A3CCQ34570325-70D534DE-2AAA-4157-B2EF-4241E9FB4D7BQ34995406-208D31C9-886C-4624-9813-B0D129FD3B86Q34997091-4B924F01-6AE3-4D21-BD1C-6162FC0A15F8Q35015208-1947D5D9-9D87-4109-B72B-FB133449DF69Q35057696-603062E0-1E44-41FF-BF3E-7615C97B0403Q35689073-749C2673-7194-4486-8C8C-22BCD5461841Q35689099-44AC1212-6AD6-447D-957A-1D5E14478549Q35716191-B6F2C581-078E-4333-BE1F-7BC618A45AF1Q35759822-AA7B0B8C-23CE-436B-A522-EFA4D42F142DQ35783747-264D3D7A-5160-4996-90BC-C8E5805FD927Q35783885-2AB1A3A3-D096-42E5-B2BC-5FAA32510B87Q36118755-86E07728-1B63-4EB1-8A0F-241BB6FDAD45Q36362263-4BDBA40B-529A-4E36-85B9-311DDF9C96A4Q36421548-C7F1C740-DC66-445E-92B4-BC8D6391846EQ36474326-FA56DB56-DB4E-4462-849F-26FF6537F842Q36949951-3CB9B1D6-18C2-4129-96F1-811BC1388540Q37033022-5848E31F-EDCF-4601-9724-0B6B02587669Q37417367-4557B867-114E-4591-9452-6BA1F3FB71E8Q37451153-5DBE3C65-DA9B-4AD8-99A3-4441AB140471Q37483596-E03D5EB6-EA42-4DB9-ADDC-680ABE6FD3F3Q37683025-93B47B40-31DD-4991-8DBA-5B6830F2F697Q37972741-BA6C238D-CA9A-4ACC-874B-063BC4DE0E4EQ38123136-C9346E2E-2D53-4726-89B0-8E6347CE1A49Q38909299-CE3C8720-8EC2-4A34-9A50-9E360137CDCBQ39164566-C8497C71-D6A3-423D-8548-90C04A53E622Q39268312-F30963A5-8B9B-4C37-90DE-A50A1CAE09B1Q39278063-B747B7BD-BF82-4C24-9A99-E85F08F41B3D
P2860
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@ast
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@en
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@nl
type
label
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@ast
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@en
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@nl
prefLabel
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@ast
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@en
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@nl
P2093
P2860
P1476
Genetic alteration of capsule ...... s of Streptococcus pneumoniae.
@en
P2093
Gail G Hardy
Janet Yother
Melanie Abeyta
P2860
P304
P356
10.1128/IAI.71.1.218-225.2003
P407
P577
2003-01-01T00:00:00Z